Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 19, 2014, Pages 6952-6957

  Sacchi, Veronica ^a   Mittermayr, Rainer ^b   Hartinger, Joachim ^b   Martino, Mikaël M ^c   Lorentz, Kristen M ^c   Wolbank, Susanne ^b   Hofmann, Anna ^b   Largo, Remo A ^d   Marschall, Jeffrey S ^e,f   Groppa, Elena ^a   Gianni Barrera, Roberto ^a   Ehrbar, Martin ^e   Hubbell, Jeffrey A ^c   Redl, Heinz ^b   Banfi, Andrea ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b LUDWIG BOLTZMANN INSTITUTE FOR EXPERIMENTAL AND CLINICAL TRAUMATOLOGY   (Austria)

^c EPFL   (Switzerland)

^d Department of Urology ^*  (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALPHA SMOOTH MUSCLE ACTIN; APROTININ; BLOOD CLOTTING FACTOR 8A; FIBRIN; RECOMBINANT VASCULOTROPIN; RECOMBINANT VASCULOTROPIN A 164; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS LINKING; ENDOTHELIUM CELL; EPIDERMIS HYPERPLASIA; FEMALE; FIBRINOLYSIS; HYDROGEL; IN VIVO STUDY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; ISCHEMIA; LIMB ISCHEMIA; MALE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERICYTE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RAT; SMOOTH MUSCLE FIBER; TISSUE NECROSIS; TISSUE PERFUSION; WOUND HEALING;

ANIMALS; FEMALE; FIBRIN; GELS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HINDLIMB; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISCHEMIA; MICE; MICE, INBRED STRAINS; MICE, SCID; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84900483957     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1404605111     Document Type: Article

References (33)

1. Rissanen TT, et al. (2005) Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arteriali-zation and sprouting angiogenesis. Circulation 112(25):3937-3946.
2. Pries AR, Höpfner M, le Noble F, Dewhirst MW, Secomb TW (2010) The shunt problem: Control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 10(8):587-593.
3. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of an-giogenesis. Nature 473(7347):298-307.
4. Gupta R, Tongers J, Losordo DW (2009) Human studies of angiogenic gene therapy. Circ Res 105(8):724-736.
5. Ylä-Herttuala S, Markkanen JE, Rissanen TT (2004) Gene therapy for ischemic cardiovascular diseases: Some lessons learned from the first clinical trials. Trends Car-diovasc Med 14(8):295-300.
6. Karvinen H, Ylä-Herttuala S (2010) New aspects in vascular gene therapy. Curr Opin Pharmacol 10(2):208-211.
7. Ozawa CR, et al. (2004) Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 113(4):516-527.
8. Park JE, Keller GA, Ferrara N (1993) The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bio-activity of extracellular matrix-bound VEGF. Mol Biol Cell 4(12):1317-1326.
9. Dor Y, et al. (2002) Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 21(8):1939-1947.
10. Tafuro S, et al. (2009) Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. Cardiovasc Res 83(4):663-671.
11. Tayalia P, Mooney DJ (2009) Controlled growth factor delivery for tissue engineering. Adv Mater 21(32-33):3269-3285.
12. Banfi A, von Degenfeld G, Blau HM (2005) Critical role of microenvironmental factors in angiogenesis. Curr Atheroscler Rep 7(3):227-234.
13. Breen A, O'Brien T, Pandit A (2009) Fibrin as a delivery system for therapeutic drugs and biomolecules. Tissue Eng Part B Rev 15(2):201-214.
14. Schense JC, Bloch J, Aebischer P, Hubbell JA (2000) Enzymatic incorporation of bio-active peptides into fibrin matrices enhances neurite extension. Nat Biotechnol 18(4): 415-419.
15. Schense JC, Hubbell JA (1999) Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug Chem 10(1):75-81.
16. Ehrbar M, et al. (2004) Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res 94(8):1124-1132.
17. Schmoekel HG, et al. (2005) Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol Bioeng 89(3):253-262.
18. Lorentz KM, Yang L, Frey P, Hubbell JA (2012) Engineered insulin-like growth factor-1 for improved smooth muscle regeneration. Biomaterials 33(2):494-503.
19. Traub S, et al. (2013) The promotion of endothelial cell attachment and spreading using FNIII10 fused to VEGF-A165. Biomaterials 34(24):5958-5968.
20. Ehrbar M, et al. (2008) The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials 29(11):1720-1729.
21. Lorentz KM, Kontos S, Frey P, Hubbell JA (2011) Engineered aprotinin for improved stability of fibrin biomaterials. Biomaterials 32(2):430-438.
22. Armulik A, Genové G, Betsholtz C (2011) Pericytes: Developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 21(2):193-215.
23. Masaki I, et al. (2002) Angiogenic gene therapy for experimental critical limb ischemia: Acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 90(9):966-973.
24. Couffinhal T, et al. (1998) Mouse model of angiogenesis. Am J Pathol 152(6):1667-1679.
25. Sundberg C, et al. (2001) Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol 158(3):1145-1160.
26. Springer ML, et al. (2003) Localized arteriole formation directly adjacent to the site of VEGF-induced angiogenesis in muscle. Mol Ther 7(4):441-449.
27. Greenberg JI, et al. (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456(7223):809-813.
28. Mujagic E, et al. (2013) Induction of aberrant vascular growth, but not of normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent. Hum Gene Ther Methods 24(1):28-37.
29. von Degenfeld G, et al. (2006) Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. FASEB J 20(14):2657-2659.
30. Korpisalo P, et al. (2011) Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy. Eur Heart J 32(13):1664-1672.
31. Corral CJ, et al. (1999) Vascular endothelial growth factor is more important than basic fibroblastic growth factor during ischemic wound healing. Arch Surg 134(2): 200-205.
32. Zisch AH, Schenk U, Schense JC, Sakiyama-Elbert SE, Hubbell JA (2001) Covalently conjugated VEGF: Fibrin matrices for endothelialization. J Control Release 72(1-3): 101-113.
33. Michlits W, Mittermayr R, Schäfer R, Redl H, Aharinejad S (2007) Fibrin-embedded administration of VEGF plasmid enhances skin flap survival. Wound Repair Regen 15(3):360-367.